{
    "nctId": "NCT00914043",
    "briefTitle": "Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45",
    "officialTitle": "Biobehavioral Mechanisms of Fatigue in Patients Treated on NSABP B-45: A Phase III Clinical Trial Comparing Adjuvant Sunitinib Malate to Placebo in Women With Residual Invasive Breast Cancer Following Neoadjuvant Chemotherapy",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer, Fatigue",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Biological and behavioral predictors of fatigue in breast cancer patients at 12 and 24 months after randomization and initiation of treatment on clinical trial NSABP-B-45",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of residual invasive breast cancer\n\n  * Stage II, IIIA, or IIIB disease\n  * HER2/neu-negative disease\n* Randomized to receive either sunitinib malate or placebo on clinical trial NSABP-B-45\n\n  * Has not started therapy on clinical trial NSABP-B-45\n* Has completed baseline Behavioral and Health Outcome questionnaires on clinical trial NSABP-B-45\n* Hormone-receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}